SAB-142 Phase 1 Data Shows C-Peptide Preservation in Type 1 Diabetes Patients
SABS has more than doubled off its 52-week low of $1.
Summary
SAB Biotherapeutics reported encouraging Phase 1 data for SAB-142, showing C-peptide preservation in Type 1 Diabetes patients, supporting its disease-modifying potential.
Key Events · Product Development and Regulatory · SABS
-
Positive Phase 1 Data for SAB-142
Additional data from the Phase 1 HUMAN trial showed SAB-142 treated participants (n=4) had no decrease in C-peptide levels at Day 120 compared to baseline, while the placebo participant showed a decrease.
-
C-Peptide Preservation Observed
The data indicates early signals of C-peptide preservation, consistent with the anticipated mechanism of action for SAB-142 in adult patients with established Type 1 Diabetes.
-
Supports Phase 2b Advancement
These findings further support the advancement of SAB-142 into the registrational Phase 2b SAFEGUARD trial, which was previously announced in the 10-K filed yesterday.
Analysis · SABS · Life Sciences
SAB Biotherapeutics announced additional positive Phase 1 data for its lead candidate, SAB-142, in adult patients with established Type 1 Diabetes. The data demonstrated early signals of C-peptide preservation, a key indicator of beta cell function, which aligns with the drug's anticipated mechanism of action. This positive clinical update provides further validation for SAB-142 as it progresses into a registrational Phase 2b trial, reinforcing investor confidence in the program's potential to modify the course of T1D.
How filings like this one have moved
In the 30 days to Sep 15, 2026, 29.9% of the 1678 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was -0.25%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, SABS was trading at $3.71 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $182.8M. The 52-week trading range was $1.00 to $6.60. This filing was assessed with positive market sentiment and an importance score of 7 out of 10.